Monday’s HotCopper Trends: Opthea strife, Errawarra jumps on acquisitions, Memphasys best-in-class trial results | March 21, 2025

The Market Herald
03-24

The ASX has been trading flat at around 7,928 points.

Discretionary has been the best performing sector today, up 1%, followed by Financials, up 0.66%, and Utilities, up 0.5%.

Staples has been the worst performing, down 1%, followed by Materials, down 0.9%, and Industrials, down 0.8%.

Opthea (ASX:OPT) has been the most watched on HotCopper forums today and is in a trading halt. Its COAST Phase 3 trial failed to meet primary endpoint of mean change in best corrected visual acuity from baseline to Week 52. The company is now considering the overall impact of the negative trial result heading into the year.

Also trending: Errawarra Resources (ASX:ERW), which has entered binding agreements to acquire 70% of the historical Elizabeth Hill Silver Project, 70% of the silver rights to the Pinderi Hills Project tenement package, and 70% of the ownership of three tenements  surrounding the silver project.

Rounding out the most discussed has been Memphasys (ASX: MEM), which unveiled the successful unblinding and data analysis of its pivotal clinical trial for the Felix System, confirming its best-in-class performance in sperm selection for Assisted Reproductive Technology.

You’re up to date, see you later for market close.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10